What it's for (Indications)
- Fluphenazine is a potent antipsychotic agent primarily indicated for the management of manifestations of psychotic disorders.
- It is particularly effective in the treatment of schizophrenia, including chronic forms, and is often utilized for long-term maintenance therapy, especially its decanoate formulation which allows for less frequent dosing and improved medication adherence.
- This medication helps in reducing the severity of positive symptoms such as hallucinations, delusions, and disorganized thought patterns, thereby improving overall functioning and quality of life for individuals grappling with these debilitating conditions.
- The therapeutic benefits extend to individuals requiring sustained pharmacological intervention to prevent relapse and maintain symptomatic control over extended periods, making it a cornerstone in the chronic management of severe psychiatric conditions.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage of fluphenazine must be highly individualized and is dependent on the patient's condition, response, and the specific formulation used (e.g., fluphenazine hydrochloride tablets/elixir or fluphenazine decanoate injection). For oral fluphenazine hydrochloride, initial doses typically range from 0.5 mg to 10 mg daily, administered in divided doses, with some severe cases potentially requiring up to 20 mg per day under close medical supervision. For intramuscular fluphenazine hydrochloride, an initial dose of 1.25 mg may be given, not exceeding 10 mg daily. Fluphenazine decanoate, a long-acting injectable formulation, is usually initiated at 12.5 mg to 25 mg every 1 to 4 weeks, depending on the patient's prior response to oral fluphenazine and overall clinical status. The lowest effective dose should always be sought to minimize the risk of adverse effects, and dosage adjustments should be made gradually, with careful monitoring of clinical response and side effect profile to ensure optimal therapeutic outcomes and patient safety. |
Safety & Warnings
Common Side Effects
- Fluphenazine, like other typical antipsychotics, is associated with a range of side effects, prominently including extrapyramidal symptoms (EPS).
- These can manifest as acute dystonia (sustained muscle contractions), akathisia (inner restlessness), parkinsonism (tremor, rigidity, bradykinesia), and potentially irreversible tardive dyskinesia (involuntary, repetitive movements, especially of the face and tongue) with long-term use.
- Other common adverse effects include anticholinergic effects such as dry mouth, blurred vision, constipation, and urinary retention.
- Sedation, orthostatic hypotension (leading to dizziness or falls), and weight gain are also frequently reported.
- Endocrine effects like hyperprolactinemia, which can lead to galactorrhea, amenorrhea, and sexual dysfunction, may occur.
- Less common but serious side effects include neuroleptic malignant syndrome (NMS), agranulocytosis, QT prolongation, seizures, and photosensitivity.
- Patients should be closely monitored for all potential adverse reactions throughout treatment, and any concerning symptoms should be reported to a healthcare provider immediately.
Serious Warnings
- Black Box Warning: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Fluphenazine, like other antipsychotic drugs, is not approved for the treatment of dementia-related psychosis. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality in elderly patients with dementia-related psychosis. This increased mortality may not be attributable to the specific drug class but rather to patient characteristics. This medication should not be used in this population due to these serious risks.
- Several serious warnings are associated with fluphenazine therapy.
- Neuroleptic Malignant Syndrome (NMS), a rare but potentially fatal condition characterized by hyperpyrexia, muscle rigidity, altered mental status, and autonomic instability, requires immediate discontinuation of the drug and intensive symptomatic treatment.
- Tardive Dyskinesia (TD), often irreversible, can develop during or after therapy; the risk increases with treatment duration and cumulative dose, emphasizing the importance of using the lowest effective dose for the shortest possible duration.
- Patients, especially elderly individuals, are at increased risk for orthostatic hypotension, leading to falls.
- Fluphenazine can lower the seizure threshold, necessitating caution in patients with a history of seizure disorders.
- Anticholinergic effects require careful use in patients with prostatic hypertrophy or narrow-angle glaucoma.
- Hematologic abnormalities, including leukopenia and agranulocytosis, though rare, warrant periodic blood count monitoring.
- Furthermore, impairment of the body's ability to regulate core temperature and potential QT interval prolongation necessitates careful patient assessment and monitoring, particularly in those with pre-existing cardiovascular conditions or electrolyte imbalances.
How it Works (Mechanism of Action)
Fluphenazine's therapeutic efficacy as an antipsychotic agent primarily stems from its potent antagonism of dopamine D2 receptors in the central nervous system, particularly within the mesolimbic pathway of the brain. This blockade of dopaminergic neurotransmission is believed to alleviate positive symptoms of psychosis, such as hallucinations and delusions. Beyond D2 receptor antagonism, fluphenazine also exerts antagonist effects on several other receptor systems, including serotonin 5-HT2A, alpha-1 adrenergic, histamine H1, and muscarinic cholinergic receptors. The blockade of dopamine D2 receptors in the nigrostriatal pathway is thought to be responsible for the common extrapyramidal side effects associated with fluphenazine. Its anticholinergic activity contributes to side effects like dry mouth and constipation, while H1 receptor blockade can cause sedation. The broad receptor binding profile contributes to both its therapeutic effects and its diverse side effect profile, making it a powerful yet carefully managed medication.